LANCE SCOTT, M.D.
Ophthalmology Physician · OKLAHOMA CITY, OK
Individual Active NPI 1417958059
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,422 | 90,664 | $10,130,654 | $4,805,921 | $3,776,622 |
| 2023 | 1,446 | 70,339 | $9,822,883 | $4,766,810 | $3,738,788 |
| 2022 | 1,290 | 21,590 | $6,611,929 | $3,320,055 | $2,598,821 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | 73,560 | $35 | $27 |
| 92134 | Imaging of retina | 3,375 | $39 | $29 |
| J2782 | Injection, avacincaptad pegol, 0.1 mg | 2,600 | $109 | $87 |
| 67028 | Injection of drug into eye | 2,393 | $115 | $85 |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 2,175 | $168 | $134 |
| 92014 | Established patient complete exam of visual system | 1,961 | $120 | $83 |
| J2778 | Injection, ranibizumab, 0.1 mg | 1,657 | $159 | $126 |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 1,380 | $147 | $117 |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 611 | $226 | $180 |
| 92004 | New patient complete exam of visual system | 299 | $142 | $99 |
| J0178 | Injection, aflibercept, 1 mg | 194 | $713 | $574 |
| J9035 | Injection, bevacizumab, 10 mg | 87 | $65 | $51 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Ophthalmology Physician | 207W00000X | ✓ | 27666 | OK |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Ophthalmology Physician providers in Oklahoma
- NPI 1508446964
- NPI 1346610375
- NPI 1548846991
- NPI 1194951657
- NPI 1942272372
- NPI 1285772160
- NPI 1336568146
- NPI 1518129956
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.